Links For Press Note

Links For Press Note

The novel coronavirus disease has now infiltrated hitherto over 250 000 cases have been reported from the country. With a population of more than 1.3 billion people, India could become the new epicenter of COVID-19. Due to the remarkable population density, poor socioeconomic conditions, and health care resources, the World Health Organization (WHO) recently stated that the “future of the pandemic will depend on how India handles it.” Here, we are sending some important links related to the present scenario of COVID-19 in India, the country’s response and the major challenges that lie in the road ahead.

Explained: WHO classifies India variant as being of global concern. What does it mean?

The World Health Organization on Monday classified a coronavirus variant first identified in India as a “global variant of concern”. This variant called B.1.617 was classified as a variant under investigation (VUI) by authorities in the UK earlier in May. It has already spread to more than 17 countries and several countries have put travel restrictions for passengers coming from India

DCGI gives nod to anti-COVID-19 drug made by INMAS, Dr Reddy’s Labs

An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy’s Laboratories (DRL), Hyderabad.Clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients. The drug will be of immense benefit to the people suffering from COVID-19.